Researchers have generated the first immortalised cell lines which allow more efficient manufacture of red blood cells. The team, from the University of Bristol and NHS Blood and Transplant, were able to manufacture red blood cells in a more efficient scale than was previously possible.
In the first randomized, double-blinded trial of an online behavioral intervention for high blood pressure, participants in web-based lifestyle counseling reduced their systolic blood pressure (the higher number in a blood-pressure reading) by 10 mmHg, compared with a 6 mmHg reduction for those taking part in a web-based control intervention, a statistically significant difference. The research was presented at the American College of Cardiology’s 66th Annual Scientific Session.
A new class of cholesterol lowering drugs known as PCSK9 inhibitors has emerged as an effective treatment for drastically lowering LDL cholesterol beyond what is possible with statin therapy alone. Previous research demonstrated that evolocumab, a member of this new class of drugs, effectively reduces LDL cholesterol by approximately 60 percent. The FOURIER trial (Further Cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk) was designed to determine whether evolocumab, when added to statin therapy, would reduce adverse cardiovascular events.
A form of RNA released from fat cells into the blood may help to regulate other tissues.
CRISPR Gene-Repair Strategy Shows Promise for Treatment of Blood Disorders